Optimizing therapeutic approaches for HR+/HER2-advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression
Juan Miguel Cejalvo Andújar, Francisco Ayala de la Peñ, Mireia Margeli Vila, Javier Pascual, Pablo Tolosa, Cristina Pages, Mónica Cuenca, Ángel Guerrero Zotano*
Producció científica: Contribució a revista › Article de revisió › Recerca › Avaluat per experts
5Citacions
(Web of Science)
Fingerprint
Navegar pels temes de recerca de 'Optimizing therapeutic approaches for HR+/HER2-advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression'. Junts formen un fingerprint únic.